Teva Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS
TEVA PHARMS has three hundred and thirty-six approved drugs.
There are two US patents protecting TEVA PHARMS drugs. There are forty tentative approvals on TEVA PHARMS drugs.
Summary for Teva Pharms
| US Patents: | 2 |
| Tradenames: | 279 |
| Ingredients: | 273 |
| NDAs: | 336 |
Drugs and US Patents for Teva Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms | FAMCICLOVIR | famciclovir | TABLET;ORAL | 077487-002 | Aug 24, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms | MYCOPHENOLATE MOFETIL | mycophenolate mofetil | TABLET;ORAL | 065457-001 | May 4, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065227-003 | Mar 15, 2007 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Teva Pharms Usa | EFINACONAZOLE | efinaconazole | SOLUTION;TOPICAL | 211827-001 | Dec 16, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 9,399,025 | ⤷ Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,939,539 | ⤷ Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,620,847 | ⤷ Start Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 5,981,589 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
International Patents for Teva Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 03020252 | ⤷ Start Trial |
| European Patent Office | 1443933 | ⤷ Start Trial |
| Germany | 60234708 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1140840 | CA 2007 00002 | Denmark | ⤷ Start Trial | PRODUCT NAME: SORAFENIB TOSYLAT |
| 1884242 | 132014902294693 | Italy | ⤷ Start Trial | PRODUCT NAME: LURASIDONE, OPZIONALMENTE IN FORMA DI BASE LIBERA O DI SUOI SALI FARMACEUTICAMENTE ACCETTABILI(LATUDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/913, 20140321 |
| 1644019 | 122013000079 | Germany | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201 |
| 0497512 | SPC/GB98/035 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: RIZATRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY RIZATRIPTAN BENZOATE; REGISTERED: NL 21815 19980211; NL 21816 19980211; NL 21817 19980211; NL 21818 19980211; UK 00025/0369 19980624; UK 00025/0370 19980624; UK 00025/0371 19980624; UK 00025/0372 19980624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
